B
Brickell Biotech
Brickell Biotech is focused on the acquisition, development, and commercialization of drug therapies for the treatment of skin diseases
About Brickell Biotech
Originally founded as Brickell Biotech, Inc. in 2009, the company rebranded to Fresh Tracks Therapeutics in September 2022 to signify a strategic pivot towards developing therapies for autoimmune and inflammatory diseases. This shift involved divesting its dermatology asset for excessive sweating, sofpironium bromide, to Botanix Pharmaceuticals. The company was co-founded by Reginald Hardy and Andrew Sklawer, who were instrumental in shaping its strategic direction, including the acquisition of novel drug candidates.
The company operated as a clinical-stage pharmaceutical firm focused on creating prescription therapeutics for debilitating autoimmune and inflammatory conditions. Its business model centered on identifying and acquiring promising drug candidates, developing them through clinical trials, and then seeking strategic partnerships or sale of the assets. For instance, the company acquired a DYRK1A inhibitor platform from Voronoi, a South Korean company, and a preclinical STING inhibitor from Carna Biosciences. The executive team, including former CEO Robert Brown who joined in 2019 from Eli Lilly, had a background in developing and commercializing major pharmaceutical products.
Fresh Tracks' pipeline featured several new molecular entities targeting novel pathways in immunology. Its lead candidate was FRTX-02, a first-in-class, orally available DYRK1A inhibitor designed to restore immune balance by modulating both adaptive and innate immune responses. Preclinical models showed promise in treating conditions like atopic dermatitis and rheumatoid arthritis. The company also had a preclinical oral STING (stimulator of interferon genes) inhibitor, FRTX-10, for autoinflammatory diseases. However, in September 2023, after a search for strategic alternatives like a merger or acquisition proved unsuccessful, the company announced its dissolution. It discontinued all development programs and announced a planned liquidation of assets, with a final dissolution date set for February 28, 2025.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2009
- Headquarters
- Boulder, United States
- Listing
- IPO 2019
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 54.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Jul 2021 | $8.1M | — | Undisclosed | — |
| IPO✓Exit | Sep 2019 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $8M | 0% |
| 2025 | $8M | 0% |
| 2024 | $8M | 0% |
| 2023 | $8M | +15.3% |
| 2022 | $6.9M | +1618.6% |
| 2021 | $404K | -77.8% |
| 2020 | $1.8M | — |
Growth signals
Latest recorded traffic for Brickell Biotech is 150 monthly website visits, down 88.5% over the last three months. Brickell Biotech's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
AMOREPACIFIC Ventures- PMPalisade Capital Management
Other known investors3 additional known investors
Elevate Ventures
Hercules Capital
VisionTech Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Brickell Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Brickell Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.